# åˆ¶è¯æ—¥æŠ¥ Pharma Daily

**æ—¥æœŸ**: 2026-01-28
**æ›´æ–°æ—¶é—´**: 2026-01-29 04:06
**æ–°é—»æ•°é‡**: 104

---

## ä»Šæ—¥æ¦‚è§ˆ

## ğŸ“Š AI æ™ºèƒ½åˆ†æ

### ä»Šæ—¥æ¦‚è§ˆ

ä»Šæ—¥åˆ¶è¯è¡Œä¸šåŠ¨æ€èšç„¦äºåŸºå› ç¼–è¾‘ä¸ç»†èƒæ²»ç–—é¢†åŸŸçš„é‡è¦è¿›å±•ï¼Œå…¶ä¸­Intelliaçš„CRISPRç–—æ³•ä¸´åºŠè¯•éªŒéƒ¨åˆ†æ¢å¤ä»¥åŠCellareså®Œæˆ2.57äº¿ç¾å…ƒèèµ„ä¸ºè¡Œä¸šäº®ç‚¹ã€‚åŒæ—¶ï¼Œå¼ºç”Ÿæ——ä¸‹Darzalex Fasproè·å¾—FDAæ–°é€‚åº”ç—‡æ‰¹å‡†ï¼Œå·©å›ºå…¶åœ¨å¤šå‘æ€§éª¨é«“ç˜¤æ²»ç–—é¢†åŸŸçš„åœ°ä½ã€‚æ­¤å¤–ï¼Œç¤¼æ¥ä¸Seamless Therapeuticsè¾¾æˆè¶…10äº¿ç¾å…ƒåŸºå› ç¼–è¾‘åˆä½œï¼Œæ˜¾ç¤ºå‡ºå¤§å‹è¯ä¼æŒç»­åŠ ç é—ä¼ åŒ»å­¦é¢†åŸŸã€‚

### ğŸ”¥ é‡ç‚¹æ–°é—»

**2. FDA lifts hold on an Intellia CRISPR drug trial** â­â­â­â­â­
   - ç±»åˆ«: ä¸´åºŠè¯•éªŒ
   - FDAè§£é™¤å¯¹Intelliaå…³é”®CRISPRåŸºå› ç¼–è¾‘ç–—æ³•ä¸´åºŠè¯•éªŒçš„éƒ¨åˆ†æš‚åœï¼Œæ ‡å¿—ç€åŸºå› ç¼–è¾‘é¢†åŸŸç›‘ç®¡çš„é‡è¦è¿›å±•

**3. FDA approves daratumumab and hyaluronidase-fihj with bortezomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma** â­â­â­â­â­
   - ç±»åˆ«: ç›‘ç®¡å®¡æ‰¹
   - FDAæ‰¹å‡†Darzalex Fasproè”åˆç–—æ³•ç”¨äºæ–°è¯Šæ–­å¤šå‘æ€§éª¨é«“ç˜¤ï¼Œä¸ºæ‚£è€…æä¾›é‡è¦æ–°æ²»ç–—é€‰æ‹©

**5. Cellares raises $257M to fund global expansion as it eyes 2027 IPO** â­â­â­â­
   - ç±»åˆ«: å•†ä¸šåŠ¨æ€
   - ç»†èƒç–—æ³•åˆ¶é€ å•†Cellareså®Œæˆ2.57äº¿ç¾å…ƒDè½®èèµ„ï¼Œä¸º2027å¹´IPOåšå‡†å¤‡ï¼Œæ˜¾ç¤ºç»†èƒæ²»ç–—é¢†åŸŸæŒç»­å—èµ„æœ¬é’ç

**6. Lilly partners with recombinase-based gene editing startup Seamless Therapeutics** â­â­â­â­
   - ç±»åˆ«: å•†ä¸šåŠ¨æ€
   - ç¤¼æ¥ä¸é‡ç»„é…¶åŸºå› ç¼–è¾‘åˆåˆ›å…¬å¸è¾¾æˆè¶…11äº¿ç¾å…ƒåˆä½œï¼Œè¿›ä¸€æ­¥å¸ƒå±€é—ä¼ åŒ»å­¦é¢†åŸŸ

**14. Regenxbio gene therapy trials suspended by FDA over safety worries** â­â­â­â­
   - ç±»åˆ«: ä¸´åºŠè¯•éªŒ
   - FDAå› å®‰å…¨æ€§é—®é¢˜æš‚åœRegenxbioä¸¤é¡¹åŸºå› ç–—æ³•è¯•éªŒï¼Œå‡¸æ˜¾åŸºå› æ²»ç–—å®‰å…¨æ€§ç›‘ç®¡çš„é‡è¦æ€§

### ğŸ“ åˆ†ç±»æ‘˜è¦

**æ–°è¯ç ”å‘** (Drug R&D): ä»Šæ—¥æ–°è¯ç ”å‘åŠ¨æ€åŒ…æ‹¬siRNAç–—æ³•BWâ€‘20829è¿›å…¥IIbæœŸè¯•éªŒã€ç½—æ°å±•ç¤ºGLP-1æ³¨å°„å‰‚æ–°æ•°æ®ã€ä»¥åŠå¤šç§åŸºå› ç¼–è¾‘å’Œç»†èƒæ²»ç–—æŠ€æœ¯çš„è¿›å±•ï¼Œæ˜¾ç¤ºè¡Œä¸šæŒç»­å‘ç²¾å‡†åŒ»ç–—å’Œå…ˆè¿›ç–—æ³•è½¬å‹ã€‚
**ä¸´åºŠè¯•éªŒ** (Clinical Trials): ä¸´åºŠè¯•éªŒé¢†åŸŸå‡ºç°é‡è¦ç›‘ç®¡å˜åŒ–ï¼ŒIntelliaçš„CRISPRç–—æ³•è¯•éªŒéƒ¨åˆ†æ¢å¤ï¼Œè€ŒRegenxbioçš„åŸºå› ç–—æ³•è¯•éªŒå› å®‰å…¨æ€§é—®é¢˜è¢«æš‚åœï¼Œå‡¸æ˜¾ä¸´åºŠè¯•éªŒä¸­é£é™©ä¸ç›‘ç®¡çš„å¹³è¡¡ã€‚

### ğŸ”® æ˜æ—¥å…³æ³¨

éœ€å…³æ³¨FDA/MHRA/Health Canadaå°†äº2æœˆ6æ—¥ä¸¾è¡Œçš„ç›‘ç®¡ç ”è®¨ä¼šï¼Œä¼šè®®å°†è®¨è®ºè‰¯å¥½ä¸´åºŠå®è·µã€ç”Ÿç‰©ç­‰æ•ˆæ€§å’Œè¯ç‰©è­¦æˆ’ç­‰è®®é¢˜ï¼Œå¯èƒ½å½±å“æœªæ¥ä¸´åºŠè¯•éªŒè®¾è®¡å’Œç›‘ç®¡è¦æ±‚ã€‚åŒæ—¶ï¼Œæ¬§ç›Ÿä¸å°åº¦è‡ªç”±è´¸æ˜“åå®šä¸­å…³äºè¯å“å‡ºå£å…³ç¨çš„è°ˆåˆ¤è¿›å±•å€¼å¾—å…³æ³¨ï¼Œå¯èƒ½å½±å“å…¨çƒåˆ¶è¯ä¾›åº”é“¾æ ¼å±€ã€‚


---

## æ•°æ®ç»Ÿè®¡

| ç±»åˆ« | æ•°é‡ |
|------|------|
| ç»¼åˆ (ç»¼åˆ) | 42 |
| æ–°è¯ç ”å‘ (Drug R&D) | 34 |
| ç›‘ç®¡å®¡æ‰¹ (Regulatory) | 20 |
| å•†ä¸šåŠ¨æ€ (Business/M&A) | 8 |

---

## ç»¼åˆ | ç»¼åˆ

### ğŸ‡ºğŸ‡¸ Responding to tougher FDA standards, Recipharm debuts new facility for beta-lactam drugs

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-26 09:13
- **é‡è¦æ€§**: â­â­â­â­â­

> Juggling a mix of customer demand and new regulations, Recipharm has built out a new facility in Bengaluru, India, to produce nonbacterial beta-lactam tablets. By commissioning the plant, Recipharm says it has lassoed up a â€œmajor partnershipâ€ with an unnamed, â€œleading innovative biopharmaceutical companyâ€ to help produce the partner's non-bacterial beta-lactam tablets.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/manufacturing/fda-winds-changing-recipharm-debuts-purpose-built-plant-beta-lactam-drugs)

---

### ğŸ‡ºğŸ‡¸ Antheia seals 2nd series C funding close, hitting more than $175M in a year

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-28 08:26
- **é‡è¦æ€§**: â­â­

> Biosynthesis specialist Antheia has topped off its series C funding with a second close, adding $24 million more to its haul. The financing lift brings Antheia's total funding over the past year to more than $175 million when combined with other capital and new contracts with the U.S. government, according to the company.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/manufacturing/antheia-seals-second-close-series-c-funding-hit-175m-year)

---

### ğŸ‡ºğŸ‡¸ J&amp;J sharpens Darzalex's edge with quadruplet FDA nod in newly diagnosed multiple myeloma

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-27 18:23
- **é‡è¦æ€§**: â­â­

> A new FDA nod for autologous stem cell transplant-ineligible patients fortifies Darzalex Faspro's position for patients with newly diagnosed multiple myeloma.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/jjs-darzalex-faspro-expands-its-first-line-offerings-fda-nod-quadruplet-multiple-myeloma)

---

### ğŸ‡ºğŸ‡¸ EU looks to knock out pharmaceutical export tariffs in sweeping free trade pact with India

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-27 11:13
- **é‡è¦æ€§**: â­â­

> Nearly two decades after the parties first floated the idea of a free trade agreement, the turbulence of the global market has prompted the European Union and India to carry their deal across the finish line.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/eu-looks-knock-out-pharmaceutical-export-tariffs-sweeping-free-trade-pact-india)

---

### ğŸ‡ºğŸ‡¸ STAT+: Pharmalittle: Weâ€™re reading about Medicare drug prices, the EU-India trade deal, and more

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-28 14:00
- **é‡è¦æ€§**: â­â­

> The Trump administration released the next 15 drugs subject to Medicare price negotiation, including for the first time treatments administered in doctor offices

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/pharmalot/2026/01/28/medicare-pharma-india-europe-novo-lilly-advertising/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Pharmalittle: Weâ€™re reading about pharma lobbying, an FDA gene-editing pathway, and more

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-26 14:05
- **é‡è¦æ€§**: â­â­

> The pharmaceutical industry, long one of the most powerful lobbies in Washington, is spending more than ever to influence the nationâ€™s capital

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/pharmalot/2026/01/26/pharma-lobbying-novo-genes-fda-patents/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Pharmalittle: Weâ€™re reading about drug shortages, llama antibodies for developing meds, and more

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-23 14:27
- **é‡è¦æ€§**: â­â­

> The number of ongoing prescription drug shortages rose slightly in the last quarter of 2025, but remained significantly lower than the all-time high reached in 2024

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/pharmalot/2026/01/23/moderna-vaccines-cigna-shortages-cancer-obesity-weight/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: The number of new drug shortages in U.S. hits lowest level in 20 years, but myriad problems remain

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-22 17:40
- **é‡è¦æ€§**: â­â­

> The number of ongoing prescription drug shortages rose slightly in the last quarter of 2025, but remained significantly lower than the all-time high reached in the beginning of 2024.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/pharmalot/2026/01/22/medicines-pharma-biotech-shortages-hospitals-injectables/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ Teva taps â€˜SNLâ€™ alum Will Forte to join Huntingtonâ€™s disease awareness push

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-26 15:42
- **é‡è¦æ€§**: â­

> Following in the footsteps of Phathom Pharmaceuticals' and Allergan Aestheticsâ€™ own partnerships with â€œSaturday Night Liveâ€ stars, Teva Pharmaceuticals is turning to a famous funnyman to tackle a not-so-funny topic.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/marketing/teva-taps-snl-alum-will-forte-join-huntingtons-disease-awareness-push)

---

### ğŸ‡ºğŸ‡¸ Arcutis, Kowa part ways on US marketing partnership for Zoryve

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-26 11:15
- **é‡è¦æ€§**: â­

> The companies had committed to a five-year partnership in July 2024, in which Kowa agreed to promote the topical treatment to primary care physicians to extend the med's reach beyond dermatologists.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/marketing/arcutis-kowa-cut-ties-two-years-us-marketing-partnership-arcutis-topical-zorvye)

---

### ğŸ‡ºğŸ‡¸ Anti-vaccine sentiment pushes Moderna away from new late-stage infectious disease trials

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-23 11:55
- **é‡è¦æ€§**: â­

> As the Trump administration erodes U.S. infrastructure supporting infectious disease vaccines, mRNA heavyweight Moderna plans to pull away from late-stage clinical trial investments in the area.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/biotech/anti-vaccine-sentiment-pushes-moderna-away-new-late-stage-infectious-disease-trials)

---

### ğŸ‡ºğŸ‡¸ STAT+: Pharmalittle: Weâ€™re reading about a Roche obesity drug, a clash over 340B claims data, and more

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-27 14:17
- **é‡è¦æ€§**: â­

> Roche plans to launch Phase 3 studies of its leading obesity candidate this quarter after the drug led to significant weight loss in a mid-stage trial

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/pharmalot/2026/01/27/roche-obesity-menopause-china-lilly-340b-hospitals-bausch/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ The new rules of biopharma M&amp;A: 4 trends driving dealmaking this year

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-28 13:36

> As biopharma M&amp;A activity ramps back up, strategy is shifting to no longer focus on securing the next blockbuster drug, but instead to ink deals that build out capabilities across the entire drug development and commercialization process.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/biotech/new-rules-biopharma-ma-4-trends-driving-deal-making-year)

---

### ğŸ‡ºğŸ‡¸ Advocacy group files FOIA lawsuit to gain further clarity on Trump administration's MFN pricing deals

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-28 15:28

> Consumer advocacy organization Public Citizen has filed a Freedom of Information Act lawsuit against the Department of Health and Human Services and the Department of Commerce&nbsp;for failing to provide documents related to President Donald Trumpâ€™s most-favored nation drug pricing deals with Pfizer and Eli Lilly.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/public-citizen-files-foia-lawsuits-against-trump-administration-mfn-pricing-deals-pfizer)

---

### ğŸ‡ºğŸ‡¸ Halozyme catches M&amp;A wave to snap up Surf Bio in delivery tech deal worth up to $400M

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-28 12:05

> Shortly after acquiring Elektrofi to beef up its subcutaneous drug delivery offerings, Halozyme Therapeutics has struck another deal to purchase Surf Bio.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/halozyme-catches-ma-wave-snap-surf-bio-delivery-tech-deal-worth-400m)

---

### ğŸ‡ºğŸ‡¸ American Academy of Pediatrics' updated immunization schedule rebukes CDC's drastic cutbacks

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-28 13:15

> The pediatric medical group recommends children be vaccinated against 18 diseases, as opposed to the federal government's recent reduction to 11.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/providers/american-academy-pediatrics-updated-immunization-schedule-rebukes-cdcs-drastic-changes)

---

### ğŸ‡ºğŸ‡¸ Teva, after third straight year of growth, expects downturn in 2026

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-28 11:01

> With a third consecutive year of sales growth under its belt, the company is expecting flat or slightly down revenues in 2026, it said.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/teva-third-year-growth-innovative-products-expects-downturn-2026)

---

### ğŸ‡ºğŸ‡¸ Ro serves up Super Bowl GLP-1 campaign starring Serena Williams

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-28 10:58

> Ro is bringing Serena Williams to the Super Bowl. Months after partnering with Williams, Ro has secured airtime at Super Bowl LX to showcase how the 23-time Grand Slam tennis championâ€™s life changed after taking GLP-1 drugs sourced from the telehealth company.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/marketing/ro-serves-serena-williams-super-bowl-glp-1-campaign)

---

### ğŸ‡ºğŸ‡¸ Cellares' series D round draws $257M as cell therapy contractor takes operations global

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-28 08:52

> With Cellares preparing to begin commercial-stage production in 2027, the California-based cell therapy contract manufacturer has taken a major step toward that goal, raising $257 million in a series D round.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/manufacturing/cellares-series-d-round-draws-257m-it-readies-commercial-production)

---

### ğŸ‡ºğŸ‡¸ Boehringer Super Bowl ad recruits Octavia Spencer, SofÃ­a Vergara for mission to boost kidney testing

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-27 14:38

> Boehringer Ingelheimâ€™s mission for Super Bowl LX viewers, should they choose to accept it, is to learn more about urine albumin-to-creatinine ratio screening to monitor kidney health in people with certain risk factors.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/marketing/boehringer-super-bowl-ad-recruits-octavia-spencer-sofia-vergara-mission-boost-kidney)

---

### ğŸ‡ºğŸ‡¸ Trump administration rolls out 15 more high-profile drugs for IRA price negotiations

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-27 17:14

> Even as the Trump administration works to implement its most-favored-nation pricing system, the U.S. government continues to advance efforts to negotiate Medicare drug prices as enabled by the Inflation Reduction Act.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/trump-administration-rolls-out-15-more-high-profile-drugs-ira-price-negotiations)

---

### ğŸ‡ºğŸ‡¸ China regulators suspend sale of Sun Pharma's dementia med after site inspection

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-27 11:13

> Chinaâ€™s National Medical Products Administration suspended the import, sale and use of Sun's rivastigmine hydrogen tartrate capsules after a virtual site inspection uncovered manufacturing shortfalls.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/manufacturing/chinese-regulators-suspend-sale-sun-pharmas-dementia-med-after-site-inspection)

---

### ğŸ‡ºğŸ‡¸ Servier delivers 16% revenue jump, firming up â‚¬10B ambition by 2030

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-27 10:09

> After posting 16.2% revenue growth in the last financial year, Servier President Olivier Laureau said the company has moved â€œone important step closerâ€ to achieving an ambitious goal for 2030.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/servier-delivers-16-revenue-jump-firming-eu10b-ambition-2030)

---

### ğŸ‡ºğŸ‡¸ Pfizer retains top spot in vaccine maker rankings as Sanofi's slide sparks 'code red' call

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-27 10:06

> Pfizer again heads up a physician ranking of vaccine manufacturers, beating Merck &amp; Co. and Moderna to complete an unchanged top three from the last edition of the survey. But while the rankings held steady, the operating environment has changed quickly to reinforce the value of being in good standing with physicians.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/marketing/pfizer-retains-top-spot-vaccine-rankings-sanofis-slide-sparks-code-red-call)

---

### ğŸ‡ºğŸ‡¸ Siegfried extends M&amp;A streak, gaining 3 sites from SK Capital and advancing US onshoring aims

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-27 09:47

> Siegfried has signed agreements to acquire the controlled drug substance businesses of the Noramco Group and Extractas Bioscience. With the deals, Siegfried gains API sites in Wilmington, Delaware; Athens, Georgia; and Australia.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/manufacturing/siegfried-continues-its-ma-splurge-gaining-3-sites-sk-capital)

---

### ğŸ‡ºğŸ‡¸ Catalent moves to wind down operations at EU cell therapy manufacturing hub

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-26 15:01

> Catalent made a series of deals early this decade to build up its presence in Gosselies. Now, it's planning to wind down cell therapy manufacturing operations in the town.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/manufacturing/catalent-moves-wind-down-operations-eu-cell-therapy-manufacturing-hub)

---

### ğŸ‡ºğŸ‡¸ New rules, higher stakes: Biopharma plays the long game in 2026

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-26 13:20

> While 2025 was dedicated to â€œunderstanding a little bit more about the rules of this game that weâ€™re playing,â€ 2026 is all about being active players in the game, McKinsey senior partner Greg Graves said Jan. 13 at Fierce JPM Week.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/biotech/new-rules-higher-stakes-biopharma-plays-long-game-2026)

---

### ğŸ‡ºğŸ‡¸ Daiichi Sankyo navigates complexity of success as Enhertu, Datroway push for market dominance

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-26 10:28

> With Enhertu and Datroway, Daiichi Sankyo has made itself a top-tier player in antibody-drug conjugates. But the road to market leadership is growing more complex as the two AstraZeneca-partnered brands move into earlier lines of therapy while facing intensifying competition.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/daiichi-sankyo-navigates-complexity-success-enhertu-datroway-push-market-dominance)

---

### ğŸ‡ºğŸ‡¸ Lilly battles weight stigma in short film centering obesity conversation on health, not appearance

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-23 11:52

> GLP-1 giant Eli Lilly has once again taken to the medium of short film to get an important message about obesity across.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/marketing/lilly-battles-weight-stigma-short-film-centering-obesity-conversation-health-not)

---

### ğŸ‡ºğŸ‡¸ STAT+: Eli Lilly expands work on gene therapies for hearing

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-28 14:49

> And other biotech news brought to you by The Readout

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/2026/01/28/biotech-news-eli-lillly-expands-gene-therapy-for-hearing/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: More high-income countries have used compulsory licenses to gain access to meds, study finds

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-28 13:00

> More high-income countries have used compulsory licenses to gain access to meds, study finds.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/pharmalot/2026/01/28/pharma-compulsory-licenses-patents-medicines-wto/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Startup Altido Therapeutics pursues CAR-T for glioblastoma tumors

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-28 09:30

> Glioblastoma is almost always fatal. Altido Bio is trying to commercialize a CAR-T cell therapy that has shown rare promise.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/2026/01/28/gene-therapy-nick-leschly-startup-altido-therapeutics-targets-glioblastoma/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: New startup to develop a GLP-1 drug for addiction

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-27 14:40

> And other biotech news brought to you by The Readout newsletter

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/2026/01/27/biotech-news-glp-1-drug-for-addiction-startup/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Roche moves obesity drug to pivotal trials after mid-stage success

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-27 08:08

> Roche plans to launch pivotal studies of an experimental weight loss drug after a successful mid-stage trial.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/2026/01/27/roche-ct388-trials-weight-loss-obesity/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Hospital group wants Trump administration to block a new Lilly policy on 340B claims data

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-26 21:11

> The American Hospital Association is asking the Trump administration to stop Eli Lilly from enacting a new policy as part of the 340B drug discount program.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/pharmalot/2026/01/26/pharma-lilly-medicines-hospitals-340b/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Launch of Wegovy pill looks to be going strong so far

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-26 14:30

> And more biotech news brought to you by The Readout

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/2026/01/26/biotech-news-wegovy-pill-launch-holds-promise-novo-nordisk/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Up and down the ladder: The latest comings and goings

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-23 17:19

> From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/pharmalot/2026/01/23/pharma-biotech-jobs-teva-novartis-novo-lilly/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Insurers blame drugmakers, hospitals for high prices

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-23 15:26

> Plus more biotech news updates, brought to you by The Readout

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/2026/01/23/biotech-news-insurers-blame-drugmakers-hospitals-for-prices/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Health insurance execs shift blame for costly, confusing health care system

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-22 20:11

> Health insurance execs blame the high cost of health care on hospitals, doctors, and prescription drugs.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/2026/01/22/health-insurance-execs-blame-high-costs-hospitals-doctors-pharma/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: France rebuffs Trump over drug-pricing boast

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-22 15:58

> And more biotech news from The Readout newsletter

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/2026/01/22/biotech-news-2/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Pharmalittle: Weâ€™re reading about Europeâ€™s pharma supply chain, stopping GLP-1 drugs, and more

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-22 14:26

> Many patients using GLP-1 drugs like Wegovy may not regain lost weight quickly when they stop treatment, an analysis of real-world data shows

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/pharmalot/2026/01/22/europe-insulin-novo-weight-cvs-pharmacies/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Anthony Letai says NCI is more stable than perceived and is heading for a big year

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-22 09:30

> Anthony Letai says the National Cancer Institute is more stable than perceived and is heading for a big year.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/2026/01/22/national-cancer-institute-director-anthony-letai-q-and-a/?utm_campaign=rss)

---

## æ–°è¯ç ”å‘ | Drug R&D

### ğŸ‡ºğŸ‡¸ FDA lifts hold on an Intellia CRISPR drug trial

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-01-27 16:59
- **é‡è¦æ€§**: â­â­â­â­

> Intellia is instituting new safeguards following the death of a study participant that led regulators to pause two trials in people with transthyretin amyloidosis. One of those tests remains suspended.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.biopharmadive.com/news/intellia-fda-lifts-hold-nex-z-crispr-ttr-amyloidosis/810584/)

---

### ğŸ‡ºğŸ‡¸ Cellares raises $257M to fund global expansion as it eyes 2027 IPO

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-28 12:00
- **é‡è¦æ€§**: â­â­â­

> Clinical-stage cell therapy manufacturer Cellares has raised $257 million in a Series D round as it gears up commercially and prepares to go public. Cellares aims to launch its commercial cell therapy manufacturing services in ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/cellares-raises-257m-to-fund-global-expansion-as-it-eyes-2027-ipo/)

---

### ğŸ‡ºğŸ‡¸ Lilly partners with recombinase-based gene editing startup Seamless Therapeutics

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-28 12:00
- **é‡è¦æ€§**: â­â­â­

> Seamless Therapeutics, a startup developing a new form of gene editing based on enzymes called recombinases, has struck a partnership with Eli Lilly that could be worth more than $1.12 billion, the company announced Wednesday ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/lilly-partners-with-startup-developing-recombinase-based-gene-editing/)

---

### ğŸ‡ºğŸ‡¸ FDA lifts hold on one of two Phase 3 gene editing studies by Intellia

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-27 15:52
- **é‡è¦æ€§**: â­â­â­

> The FDA has allowed Intellia Therapeutics to resume one of its two pivotal trials of a gene editing therapy for transthyretin amyloidosis, which is a disease caused by misfolded proteins. Intellia

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/fda-lifts-hold-on-one-of-two-phase-3-gene-editing-studies-by-intellia/)

---

### ğŸ‡ºğŸ‡¸ Lilly bets on Seamless, delving further into genetic medicine for hearing loss

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-01-28 19:09
- **é‡è¦æ€§**: â­â­

> The potentially $1 billion alliance centered around a flexible gene editing technology adds to a portfolio of cutting-edge treatments the company is developing for hearing disorders.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.biopharmadive.com/news/eli-lilly-seamless-deal-gene-editing-hearing-loss/810694/)

---

### ğŸ‡ºğŸ‡¸ Regenxbio gene therapy trials suspended by FDA over safety worries

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-01-28 16:06
- **é‡è¦æ€§**: â­â­

> The development of a brain tumor in a study participant led regulators to suspend a Hurler syndrome therapy in early testing and a treatment for Hunter syndrome nearing an FDA decision.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.biopharmadive.com/news/regenxbio-fda-hold-hunter-hurler-syndrome-gene-therapy/810691/)

---

### ğŸ‡ºğŸ‡¸ Roche, trailing in obesity, showcases new data for GLP-1 shot

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-01-27 16:31
- **é‡è¦æ€§**: â­â­

> A drug Roche acquired in a multibillion-dollar deal could be as effective as Zepbound, but may struggle to stand out in a crowded field, analysts said.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.biopharmadive.com/news/roche-obesity-drug-phase-2-data-carmot-glp-gip/810578/)

---

### ğŸ‡ºğŸ‡¸ An immune drug developer raises $50M to finance its eczema drug testing

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-01-27 15:53
- **é‡è¦æ€§**: â­â­

> TRex Bio banked a Series B extension to advance its atopic dermatitis program, which is competing in a crowded field.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.biopharmadive.com/news/trex-bio-series-b-extension-atopic-dermatitis/810617/)

---

### ğŸ‡ºğŸ‡¸ Chinaâ€™s edge in early-stage drugmaking â€˜likely to persist,â€™ Pitchbook says

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-01-26 19:15
- **é‡è¦æ€§**: â­â­

> The ongoing surge in licensing deals for early drug prospects should continue this year and involve more cell and gene therapies, which have had trouble securing funding in the U.S., the firm said in a new report.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.biopharmadive.com/news/china-biotech-drug-licensing-trends-pitchbook-cell-gene-therapy/810478/)

---

### ğŸ‡ºğŸ‡¸ Biotech investor Cormorant secures $150M for another SPAC deal

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-01-26 14:43
- **é‡è¦æ€§**: â­â­

> Amid a rebound in SPAC activity, the prolific &ldquo;crossover&rdquo; investor is aiming for its third blank-check merger since 2022 following deals with Moonlake Immunotherapeutics and BridgeBio Oncology Therapeutics.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.biopharmadive.com/news/cormorant-helix-iii-spac-deal-biotech-merger-ipo/810436/)

---

### ğŸ‡ºğŸ‡¸ Oral Rogaine maker Veradermics looks to raise $181M from IPO

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-28 19:18
- **é‡è¦æ€§**: â­â­

> Veradermics, a biotech in late-stage testing with an oral version of Rogaine, is looking to raise $181.8 million in net proceeds from its proposed IPO. The Connecticut biotech will garner that amount if it sells ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/oral-rogaine-maker-veradermics-looks-to-raise-181m-from-ipo/)

---

### ğŸ‡ºğŸ‡¸ FDA asks court to pause Louisiana's abortion pill fight

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-28 19:18
- **é‡è¦æ€§**: â­â­

> The Trump administration is asking a federal court to halt a case over the abortion pill mifepristone while the FDA undertakes a review of the drugâ€™s safety protocols. An ongoing mifepristone review could result in ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/fda-asks-court-to-pause-louisianas-abortion-pill-fight/)

---

### ğŸ‡ºğŸ‡¸ FDA suspends two Regenxbio gene therapy trials after patient developed brain tumor

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-28 15:56
- **é‡è¦æ€§**: â­â­

> The FDA has placed studies of two gene therapies from Regenxbio on hold after a five-year-old patient in one of the trials was found to have a brain tumor. The drug regulator's decision is a ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/fda-suspends-regenxbio-gene-therapy-trials-after-patient-developed-brain-tumor/)

---

### ğŸ‡ºğŸ‡¸ Eikon seeks $273M IPO with pipeline led by Chinese cancer drugs

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-28 15:25
- **é‡è¦æ€§**: â­â­

> A biotech led by former Merck top brass with a pipeline anchored by three cancer drugs linked to Chinese drug developers is pushing ahead with an IPO, even while off its peak valuation. Eikon Therapeutics ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/eikon-seeks-273m-ipo-with-pipeline-led-by-chinese-cancer-drugs/)

---

### ğŸ‡ºğŸ‡¸ Biopharma Sentiment Index | Q1 2026

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-28 12:45
- **é‡è¦æ€§**: â­

> The latest BPSI shows signs of a more durable phase in the biopharma recovery, with improvements across every metric. After four years of hunkering down, the mood in biopharma turned sharply more optimistic heading into ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/biopharma-sentiment-index-q1-2026/)

---

### ğŸ‡ºğŸ‡¸ Boehringer Ingelheim takes rare kidney disease drug to Phase 3 despite puzzling mid-stage data

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-28 11:59
- **é‡è¦æ€§**: â­

> Boehringer Ingelheimâ€™s experimental pill has shown signs of improving kidney function in patients with a rare renal condition in a mid-stage trial. But the data are somewhat confusing, with the lowest dose working better than ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/boehringer-ingelheim-takes-rare-kidney-disease-drug-to-phase-3-despite-puzzling-mid-stage-data/)

---

### ğŸ‡ºğŸ‡¸ Cardiff execs depart as company drops mixed Phase 2 data

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-27 18:22
- **é‡è¦æ€§**: â­

> Shares {$CRDF} of Cardiff Oncology fell more than 30% after the biotech disclosed mixed Phase 2 data and announced the departure of two of its top executives. San Diego-based Cardiff

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/cardiff-execs-depart-as-company-drops-mixed-phase-2-data/)

---

### ğŸ‡ºğŸ‡¸ Insilicoâ€™s latest deal is a $120M cardiometabolic drug discovery pact with Qilu Pharma

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-27 15:40
- **é‡è¦æ€§**: â­

> Insilico Medicine is having quite a month. Fresh from deals with Servier and Hygtia Therapeutics, the biotech has signed a new collaboration with Shanghai-based Qilu Pharmaceutical worth nearly ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/insilicos-latest-deal-is-a-120m-cardiometabolic-drug-discovery-pact-with-qilu-pharma/)

---

### ğŸ‡ºğŸ‡¸ AstraZeneca ends work on cardio drug; Lisata and Qilu terminate deal

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-27 14:31
- **é‡è¦æ€§**: â­

> Plus, news about Vial, Skyhawk and Gimv: AstraZeneca stops cardio drug: The UK pharma giant has terminated a Phase 1 of an oral cardio drug candidate called AZD0233, according ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/astrazeneca-ends-work-on-cardio-drug-lisata-and-qilu-terminate-deal/)

---

### ğŸ‡ºğŸ‡¸ Drugs for cancer, arthritis and HIV on Medicareâ€™s list for 2028 price cuts

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-01-28 16:51

> Still, the medications in the latest round of negotiations &mdash; which now includes &ldquo;Part B&rdquo; drugs given in doctors offices &mdash; draw very limited revenue from Medicare, an analyst pointed out.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.biopharmadive.com/news/medicare-drug-price-2028-trulicity-biktarvy-verzenio-kisqali/810688/)

---

### ğŸ‡ºğŸ‡¸ Halozyme buys a biotech startup; Cytokinetics launches heart drug

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-01-28 16:20

> Halozyme is paying as much as $400 million for a drug delivery specialist that could boost its growth prospects, one analyst wrote. Elsewhere, Boehringer dipped into China for a bispecific drug and a trans-Atlantic VC firm restocked.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.biopharmadive.com/news/halozyme-surf-myqorzo-boehringer-china-gsk-rsv-epidarex/810539/)

---

### ğŸ‡ºğŸ‡¸ Sarepta, battling slowing sales, claims Duchenne gene therapyâ€™s impact grows with time

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-01-26 16:46

> On a Monday conference call, Sarepta CEO Doug Ingram said new long-term data should help &ldquo;rebalance the discussion&rdquo; surrounding Elevidys.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.biopharmadive.com/news/sarepta-elevidys-duchenne-gene-therapy-embark-data/810461/)

---

### ğŸ‡ºğŸ‡¸ ChenMed CEO warns against GLP-1s for seniors

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-28 23:12

> ChenMed CEO Chris Chen said the primary care chain isnâ€™t encouraging the use of GLP-1 drugs for weight loss after finding the medications led to worse health outcomes among its older patients. Speaking on a ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/chenmed-ceo-warns-against-glp-1s-for-seniors/)

---

### ğŸ‡ºğŸ‡¸ Round three of IRA negotiations is expected to be â€˜manageableâ€™ for pharma

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-28 21:19

> Drugmakers will likely be able to handle the impacts of the third round of Medicare negotiations, analysts say, even as the biopharma industry continues to criticize the Biden-era program. On Tuesday, CMS

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/round-three-of-ira-negotiations-is-expected-to-be-manageable-for-pharma/)

---

### ğŸ‡ºğŸ‡¸ Lonza still intends to sell its capsules and health ingredients business

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-28 18:51

> More than a year after Lonza announced it will sell its capsules and health business, the Swiss CDMO said it has yet to finalize the deal with a buyer. A spokesperson said it has multiple ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/lonza-still-intends-to-sell-its-capsules-and-health-ingredients-business/)

---

### ğŸ‡ºğŸ‡¸ Teva CEO says it has successfully transitioned into a biopharma company

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-28 17:18

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/teva-ceo-says-it-has-successfully-transitioned-into-a-biopharma-company/)

---

### ğŸ‡ºğŸ‡¸ HHS seeks to protect drugmakers from violating anti-kickback laws ahead of TrumpRx launch

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-28 15:26

> With launch time potentially approaching for TrumpRx, HHS unveiled part of its plan to shield drugmakers from anti-kickback laws to allow them to sell their products on the new direct-to-consumer platform. The guidance â€” released via ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/hhs-seeks-to-protect-drugmakers-from-anti-kickback-laws-ahead-of-trumprx-launch/)

---

### ğŸ‡ºğŸ‡¸ Included Health launches alternative health plan

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-28 15:02

> Included Health, the virtual care and navigation company, is now offering a health plan for employers. Itâ€™s new territory for the startup, and the move puts it in a league with companies such as Centivo ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/included-health-launches-alternative-health-plan/)

---

### ğŸ‡ºğŸ‡¸ Hengrui blazes trail as Chinese drugmakers aspire to go multinational

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-28 15:00

> Jiangsu Hengrui Pharmaceuticals has quietly become a top 25 biopharma company in the world by market value. Once virtually unknown outside of China, the company has made its name overseas via an R&amp;D engine that ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/hengrui-blazes-trail-as-chinese-drugmakers-aspire-to-go-multinational/)

---

### ğŸ‡ºğŸ‡¸ Halozyme buys drug delivery biotech Surf Bio; Sanofi backs Sensorion

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-28 14:39

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/halozyme-buys-drug-delivery-biotech-surf-bio-sanofi-backs-sensorion/)

---

### ğŸ‡ºğŸ‡¸ Updated: CMS picks Lillyâ€™s Trulicity, Gilead's Biktarvy for third round of Medicare negotiations

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-27 22:26

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/cms-picks-lillys-trulicity-for-third-round-of-medicare-negotiations/)

---

### ğŸ‡ºğŸ‡¸ Hospitals could earn more for buying US-made drugs, CMS proposes

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-27 20:05

> The Trump administration's Centers for Medicare &amp; Medicaid Services is looking to incentivize hospitals to buy more domestically-produced drugs. Under a proposed rule, hospitals purchasing more than 50% of domestic-made essential ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/hospitals-could-earn-more-for-buying-us-made-drugs-cms-proposes/)

---

### ğŸ‡ºğŸ‡¸ UnitedHealth projects lower revenue in 2026 as it resets its business

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-27 18:11

> UnitedHealth Groupâ€™s turnaround plan to trade membership for improved profit margins will result in lower revenue in 2026, as the healthcare giant attempts to recover from a disastrous period of setbacks that ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/unitedhealth-projects-lower-revenue-in-2026-as-it-resets-its-business/)

---

### ğŸ‡ºğŸ‡¸ Virtual womenâ€™s health company Wisp buys TBD Health

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-27 14:00

> Wisp, a womenâ€™s telehealth company, bought sexual healthcare startup TBD Health, as virtual care companies look to become more comprehensive in the services they offer. Terms of the deal, which closed near ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/virtual-womens-health-company-wisp-buys-tbd-health/)

---

## ç›‘ç®¡å®¡æ‰¹ | Regulatory

### ğŸ‡ºğŸ‡¸ FDA approves daratumumab and hyaluronidase-fihj with bortezomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-27 19:37
- **é‡è¦æ€§**: â­â­â­â­

> On January 27, 2026, the Food and Drug Administration approved daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen Biotech, Inc.) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for adults with newly diagnosed multiple myeloma who are ineligible for autologous stem cel

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-daratumumab-and-hyaluronidase-fihj-bortezomib-lenalidomide-and-dexamethasone-newly)

---

### ğŸ‡ºğŸ‡¸ Oncology (Cancer)/Hematologic Malignancies Approval Notifications

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-27 17:55
- **é‡è¦æ€§**: â­â­â­â­

> FDA does not&nbsp;issue approval announcements for every approval or drug label update that occurs in oncology and hematology. Please refer to&nbsp;Drugs@FDA&nbsp;for the latest approvals and prescribing information for specific products.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancerhematologic-malignancies-approval-notifications)

---

### ğŸ‡ºğŸ‡¸ FDA/MHRA/Health Canada Symposium: Regulatory perspectives in good clinical practice, bioequivalence and good pharmacovigilance practice - 06/02/2026

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-26 15:26
- **é‡è¦æ€§**: â­â­â­

> This symposium will highlight current and emerging topics of interest to the industry related to good clinical practice, bioequivalence and good pharmacovigilance practice.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/news-events/fda-meetings-conferences-and-workshops/fdamhrahealth-canada-symposium-regulatory-perspectives-good-clinical-practice-bioequivalence-and)

---

### ğŸ‡ºğŸ‡¸ Medication Health Fraud for Specific Diseases and Conditions

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-28 19:11
- **é‡è¦æ€§**: â­â­

> FDA has identified condition-specific medication health fraud scams that can pose significant risks to consumers.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/medication-health-fraud/medication-health-fraud-specific-diseases-and-conditions)

---

### ğŸ‡ºğŸ‡¸ Drugs@FDA Data Files

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-28 16:31
- **é‡è¦æ€§**: â­â­

> Drugs@FDA Downloadable Data File in ZIP format, Data Definitions, and Entity Relationship Diagram (ERD)

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/drug-approvals-and-databases/drugsfda-data-files)

---

### ğŸ‡ºğŸ‡¸ A Special Year, New Seal, and Renewed Commitment to the American People

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-28 14:55
- **é‡è¦æ€§**: â­â­

> The FDA has unveiled an official agency seal which signifies the many public health strides made over 120 years.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/news-events/fda-voices/special-year-new-seal-and-renewed-commitment-american-people)

---

### ğŸ‡ºğŸ‡¸ Untitled Letters

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-27 20:21
- **é‡è¦æ€§**: â­â­

> These letters are supplied by the CDER Freedom of Information Office and only cover Office of Prescription Drug Promotion's untitled letters. FDA may have redacted or edited some of the letters to remove confidential information.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/warning-letters-and-notice-violation-letters-pharmaceutical-companies/untitled-letters)

---

### ğŸ‡ºğŸ‡¸ Project Orbis

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-27 20:13
- **é‡è¦æ€§**: â­â­

> Information Project Orbis, an initiative of the FDA Oncology Center of Excellence (OCE) that provides a framework for concurrent submission and review of oncology products among international partners.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/about-fda/oncology-center-excellence/project-orbis)

---

### ğŸ‡ºğŸ‡¸ What Does FDA Approve? Part 2

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-27 19:23
- **é‡è¦æ€§**: â­â­

> The growing spread of rumors, misinformation and disinformation about science, medicine, and the FDA, is putting patients and consumers at risk. FDA is here to provide the facts.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/consumers/consumer-updates/what-does-fda-approve-part-2)

---

### ğŸ‡ºğŸ‡¸ What's New Related to Drugs

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-27 17:56
- **é‡è¦æ€§**: â­â­

> Want to know what's new on drugs from FDA? This page provides quick links to the latest on a variety of topics including: drug approvals, safety warnings, drug shortages, etc.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/news-events-human-drugs/whats-new-related-drugs)

---

### ğŸ‡ºğŸ‡¸ Patient Listening Session Summaries

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-26 21:44
- **é‡è¦æ€§**: â­â­

> Patient Listening Session summaries are published after each session to share a high-level summary of the discussion. The Public Engagement Staff draft summaries for FDA-requested sessions and the patient community requester drafts summaries for Patient-led sessions.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/patients/fda-patient-listening-sessions/patient-listening-session-summaries)

---

### ğŸ‡ºğŸ‡¸ Generic Drugs Program Monthly and Quarterly Activities Report

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-26 18:25
- **é‡è¦æ€§**: â­â­

> Monthly and quarterly metrics of the FDA Generic Drugs Program.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/industry/generic-drug-user-fee-amendments/generic-drugs-program-monthly-and-quarterly-activities-report)

---

### ğŸ‡ºğŸ‡¸ Biosimilar Product Information

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-26 18:16
- **é‡è¦æ€§**: â­â­

> This page includes a chart of the approved biosimilar and interchangeable products. The approval of biosimilar products can improve access to care for patients by increasing the number of medication options and potentially lower costs.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/biosimilars/biosimilar-product-information)

---

### ğŸ‡ºğŸ‡¸ Patient-Focused Drug Development: Selecting, Developing, or Modifying Fit-for-Purpose Clinical Outcome Assessments

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-26 15:06
- **é‡è¦æ€§**: â­

> This guidance is the third in a series of four methodological patient-focused drug development guidances that describe how stakeholders can collect and submit patient experience data and other relevant information from patients and caregivers to be used for product development decision-making.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/regulatory-information/search-fda-guidance-documents/patient-focused-drug-development-selecting-developing-or-modifying-fit-purpose-clinical-outcome)

---

### ğŸ‡ºğŸ‡¸ Use of Bayesian Methodology in Clinical Trials of Drug and Biological Products

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-26 15:04
- **é‡è¦æ€§**: â­

> This draft guidance provides guidance to sponsors and applicants submitting investigational new drug applications (INDs), new drug applications (NDAs), biologics licensing applications (BLAs), or supplemental applications on the appropriate use of Bayesian methods in clinical trials.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-bayesian-methodology-clinical-trials-drug-and-biological-products)

---

### ğŸ‡ºğŸ‡¸ Generic Drug Facilities, Sites and Organization Lists

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-28 20:52

> Generic Drug Facilities, Sites and Organization Lists

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/industry/generic-drug-user-fee-amendments/generic-drug-facilities-sites-and-organization-lists)

---

### ğŸ‡ºğŸ‡¸ Patent Certifications and Suitability Petitions

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-27 19:00

> Information on patents and suitability petitions that impact the availability of generic drugs.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/abbreviated-new-drug-application-anda/patent-certifications-and-suitability-petitions)

---

### ğŸ‡ºğŸ‡¸ Generic Drug User Fee Amendments

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-27 17:22

> This page features news and information for industry and stakeholders about GDUFA, its fee structure, payment methods, and related information.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/industry/fda-user-fee-programs/generic-drug-user-fee-amendments)

---

### ğŸ‡ºğŸ‡¸ Center For Immunology Science, LLC - 719933 - 01/13/2026

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-27 14:20

> Sponsor/Investigator

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/center-immunology-science-llc-719933-01132026)

---

### ğŸ‡ºğŸ‡¸ Fulijaya Manufacturing SDN. BHD. - 719172 - 01/14/2026

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-27 14:20

> CGMP/Finished Pharmaceuticals/Adulterated

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/fulijaya-manufacturing-sdn-bhd-719172-01142026)

---

## å•†ä¸šåŠ¨æ€ | Business/M&A

### ğŸ‡ºğŸ‡¸ Argo Biopharma doses first patient in phase 2b trial of BWâ€‘20829

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-01-28 14:20
- **é‡è¦æ€§**: â­â­â­

> siRNA therapeutic progresses in global study for patients with elevated Lp(a)

ğŸ”— [é˜…è¯»åŸæ–‡](https://pharmatimes.com/news/argo-biopharma-doses-first-patient-in-phase-2b-trial-of-bw-20829/)

---

### ğŸ‡ºğŸ‡¸ Otsuka Pharmaceuticalâ€™s Dawnzera receives EC approval for hereditary angioedema prevention

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-01-26 12:05
- **é‡è¦æ€§**: â­â­

> Dawnzera showed an 81% reduction in the four-weekly rate of HAE attacks compared to placebo

ğŸ”— [é˜…è¯»åŸæ–‡](https://pharmatimes.com/news/otsuka-pharmaceuticals-dawnzera-receives-ec-approval-for-hereditary-angioedema-prevention/)

---

### ğŸ‡ºğŸ‡¸ ErVimmune raises 17m euros in funding to develop cancer vaccine

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-01-22 14:10
- **é‡è¦æ€§**: â­â­

> The vaccine could be created as a ready-to-use product, rather than needing to be personalised

ğŸ”— [é˜…è¯»åŸæ–‡](https://pharmatimes.com/news/ervimmune-raises-17m-euros-in-funding-to-develop-cancer-vaccine/)

---

### ğŸ‡ºğŸ‡¸ BioMed X launches kidney disease project in partnership with the government of Barbados

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-01-27 13:54
- **é‡è¦æ€§**: â­

> Initiative focuses on population-specific molecular profiling

ğŸ”— [é˜…è¯»åŸæ–‡](https://pharmatimes.com/news/biomed-x-launches-kidney-disease-project-in-partnership-with-the-government-of-barbados/)

---

### ğŸ‡ºğŸ‡¸ Akari files new patent and advances second ADC targeting CEACAM5

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-01-28 14:15

> Company strengthens pipeline with AKTX-102 as it broadens its intellectual property estate

ğŸ”— [é˜…è¯»åŸæ–‡](https://pharmatimes.com/news/akari-files-new-patent-and-advances-second-adc-targeting-ceacam5/)

---

### ğŸ‡ºğŸ‡¸ Gedeon Richter UK takes over UK rights to cariprazine

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-01-27 13:47

> Company strengthens its neuropsychiatry portfolio after marketing transfer from Recordati

ğŸ”— [é˜…è¯»åŸæ–‡](https://pharmatimes.com/news/gedeon-richter-uk-takes-over-uk-rights-to-cariprazine/)

---

### ğŸ‡ºğŸ‡¸ Corcept Therapeuticsâ€™ relacorilant plus nab-paclitaxel shows positive results in ovarian cancer

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-01-26 11:57

> Ovarian cancer is the fifth leading cause of deaths from cancer in women

ğŸ”— [é˜…è¯»åŸæ–‡](https://pharmatimes.com/news/corcept-therapeutics-relacorilant-plus-nab-paclitaxel-shows-positive-results-in-ovarian-cancer/)

---

### ğŸ‡ºğŸ‡¸ Book your tickets and join the PM Society for the 40th PM Awards on 20 March 2026

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-01-22 12:36

> The PM Awards celebrate creativity in pharmaceutical marketing and healthcare communications

ğŸ”— [é˜…è¯»åŸæ–‡](https://pharmatimes.com/news/book-your-tickets-and-join-the-pm-society-for-the-40th-pm-awards-on-20-march-2026/)

---


---

*Generated by Pharma Daily - åˆ¶è¯èµ„è®¯èšåˆç³»ç»Ÿ*

*2026-01-29 04:06:37*